September 10, 2008
U.S. National Institutes of Health (NIH) funds new $9 Million Senator Paul Wellstone Muscular Dystrophy Cooperative Research Center solely focused on facioscapulohumeral muscular dystrophy (FSH Muscular Dystrophy)
The International Center for FSHD research will be housed at BBRI and will focus on the development of Biomarkers for Therapy of FSHD.
A Cooperative Partnership of Patients & Families, Clinicians, Scientists, Government, Industry, Non-Profits & Philanthropy, Involving:
Charles Emerson, Ph.D., Boston Biomedical Research Institute [Co-Director]
Louis Kunkel, Ph.D., Children’s Hospital, Boston [Co-Director]
Acceleron Pharma
Robert J. Bloch, Ph.D., University of Maryland, Baltimore
Genzyme
Jeffrey B. Miller, Ph.D., Boston Biomedical Research Institute
Daniel Paul Perez, FSH Society, Inc.
U.S. DHHS National Institutes of Health (NIH)
Kathryn Wagner, M.D., Ph.D., The Johns Hopkins Hospital
Woodring Wright, M.D., Ph.D., University of Texas, Southwestern Medical Center
Mayana Zatz, M.Sc., Ph.D., University of Sao Paulo
The U.S. NIH FSHD Wellstone MD CRC focuses on identifying biomarkers to evaluate outcomes of clinical trials for facioscapulohumeral muscular dystrophy (FSHD) through research projects and support cores:
- Clinical Trials and Biomarkers of Myostatin Inhibition – identifying and testing biomarkers for the development of new therapies as potential FSHD treatments
- Biomarker Discovery in Muscle -- identifying key proteins and key miRNAs and their targets
- Myogenesis Studies – generating resources, repositories, data on cellular pathogenesis
- Model Studies -- exploring available and future animal models of FSHD
- Core Repository of Cells and Tissues – for FSHD researchers internationally
- Education and Training Core – creating an outstanding environment for training young scientists
To read the Special Edition of FSH Watch on the new FSHD Wellstone MD CRC, please click
HERE (PDF)
To read the Boston Biomedical Research Institute Press Release, please click
HERE (Word)
